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Can DNA Topoisomerases Minireview
Be Ribonucleases?
(59-OH). Although this covalent intermediate is chemi-
cally very stable, the steady-state concentration of this
intermediate is usually low. This is because the ligation
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San Diego, California 92182-4614 reaction is faster than the cleavage reaction. During
ligation, the 59-OH generated during cleavage displaces
the covalent DNA±enzyme intermediate in another trans-
esterification reaction and reforms the 59±39 phospho-DNA topoisomerases catalyze changes in the linkage
of DNA strands through a concerted mechanism of DNA diester linkage. A change in DNA linking number results
when strand passage occurs between the cleavage andstrand cleavage and ligation reactions (for review, see
Wang, 1996). Eukaryotic type I topoisomerases are ef- ligation steps. The cleavage and ligation reactions are
typically viewed as a pseudoequilibrium because multi-fective at relaxing supercoiled DNA, and this activity is
intimately involved in transcription and DNA replication. ple cleavage/ligation cycles can be performed on the
same substrate (Stivers et al., 1994).In addition, this activity has been directly implicated in
DNA recombination and DNA repair. These enzymes Although the normal topoisomerase reaction uses the
59-OH to attack the covalent DNA±enzyme intermediate,have been extensively studied because of their funda-
mental importance in many different biological functions it has been demonstrated that a variety of other nucleo-
philes can attack this intermediate. Forexample, a 59-OHand because topoisomerases are the target of therapeu-
tic agents for human cancer (Chen and Liu, 1996). In from another DNA strand can displace the enzyme re-
sulting in a recombinant DNA molecule. In addition,the December issue of Molecular Cell, Sekiguchi and
Shuman (1997) present biochemical evidence that eu- other hydroxyls from the solvent (e.g., glycerol) can at-
tack the intermediate (Christiansen et al., 1994). It maykaryotic topoisomerase I can also act as a site-specific
endoribonuclease. From this result, the authors postu- therefore not be surprising that a 29-hydroxyl (29-OH)
can be an active nucleophile at the ligation step of thelate that an additional biological function of topoisomer-
ases may be the identification, through cleavage, of topoisomerase reaction. In the present paper, the au-
thors demonstrate that when topoisomerase I cleavesribonucleotides misincorporated in DNA and that these
enzymes may even be involved in RNA processing reac- a phosphodiester at a ribonucleotide (see Figure 1), the
29-OH from the ribonucleotide can displace the enzymetions.
At first glance, the modulation of DNA topology and forming a 29±39 cyclic phosphate in an intramolecular
transesterification reaction (cyclization). This cyclicRNA processing may appear to be very disparate activi-
ties. However, thedata presented by Sekiguchi and Shu- phosphodiester is apparently not a substrate for topo-
isomerase cleavage and does not act as acceptor forman (1997) demonstrate that the mechanism of RNA
strand scission is similar to that used to modulate DNA attack of the 59-OH. As a result, the cyclization reaction
traps the cleaved intermediate by displacing the en-topology. Topoisomerase I from vaccinia virus was used
for these studies. This enzyme is particularly useful be- zyme. Cleaved RNA accumulates because the pseudo-
equilibrium normally associated with these reactions iscause, unlike other eukaryotic topoisomerases, the vac-
cinia enzyme exhibits high sequence specificity. Topo- destroyed.
The authors provide thorough evidence that the vac-isomerases relax supercoiled DNA by cleaving and
rejoining one strand of the duplex (see Figure 1). DNA cinia topoisomerase-mediated RNase reaction pro-
ceeds as detailed in Figure 1. First, the RNase activitycleavage is the result of a transesterification of an ac-
tive site tyrosine creating a covalent 39-phosphotyrosyl requires an active site tyrosine and a ribonucleotide at
the site of cleavage. Second, indirect evidence strongly(DNA±enzyme) intermediate and liberating a 59-hydroxyl
Figure 1. Comparison of Topoisomerase
I±Mediated Relaxation of Supercoiled DNA
and RNA Strand Cleavage
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874
argues that the cleaved RNA contains a 29, 39 cyclic The ability of an abundant enzyme, like topoisomerase
phosphate, and it is reasonable to presume that a 59-OH I, to act as a sensor for the misincorporation of ribonu-
is also generated. Third, kinetic data are consistent with cleotides is a particularly attractive possibility for several
the formation of a covalent RNA±enzyme intermediate reasons. First, the lack of sequence specificity in the
that is chased (via cyclization) into cleaved product. And DNA cleavage reaction of topoisomerase I would allow
finally, vaccinia topoisomerase I acts catalytically since ribo-directed strand scission at a broad spectrum of
it is able to turn over during the RNase reaction. sites in genomic DNA. The 29, 39 cyclic phosphate and
During vaccinia topoisomerase-mediated RNA cleav- 59-OH end would presumably be recognized as a delete-
age, greater than 90% of the RNA substrate is typically rious lesion and targeted by enzymes involved in exci-
converted to a 29, 39 cyclic product. Because the enzyme sion repair. Second, topoisomerase I is up-regulated in
is capable of converting essentially all of the RNA-con- some cancer cells, and one would expect the misincor-
taining substrate to cleaved product, it is reasonable to poration of ribonucleotides to be particularly prevalent
propose that the observed in vitro activity is not an in such rapidly dividing cells. Clearly, for any reaction
irrelevant side reaction. In addition, some ribonuclease characterized in vitro, genetic experiments are ulti-
activity is also demonstrated for human topoisomerase mately required to address biological function.
I, indicating that the reaction is not unique to vaccinia
topoisomerase I. However, further characterization is Selected Reading
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compete equally for attack on theRNA±enzyme interme-
diate provides important insight into structure/function
relationships of topoisomerases. The enzyme must align
the attacking nucleophile and the phosphodiester for
in-line attack, and the enzyme can apparently accom-
modate two nucleophiles with different chemical reac-
tivities (secondary versus primary alcohols) and different
spatial constraints. It remains to be understood how the
enzyme accommodates such a diverse array of ac-
ceptors in the ligation reaction.
It will also be important to characterize how well topo-
isomerases recognize and cleave ribonucleotides dur-
ing the first step (cleavage) of the reaction. Vaccinia
topoisomerase-mediated RNA cleavage, like the stan-
dard cleavage/ligation reaction, is sequence specific. It
is therefore tempting to speculate that vaccinia topo-
isomerase I may be involved in specific RNA processing
reactions in vivo. A specific and efficient RNA substrate
will be required before such a biological function can
be assigned. Even though no substrate is available, the
fact that another type I topoisomerase, E. coli DNA topo-
isomerase III, can act as an RNA topoisomerase (Wang
et al., 1996) does provide some credibility to this pro-
posal.
Finally, the experiments described have been per-
formed on DNA substrates containing ribonucleotides
at the cleavage site or substrates containing RNA 39 to
the cleavage site. It has been previously demonstrated
that substrates containing RNA 59 to the cleavage site
are poor substrates for vaccinia topoisomerase I. The
RNA cleavage reaction is therefore more similar to
RNase H cleavage than strict endoribonuclease activity.
However, if a biological function for topoisomerase I is to
cleave ribonucleotides that have been misincorporated
into DNA, then the observed in vitro properties are ex-
pected.
